Literature DB >> 14523165

Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants.

William Oh1, Jon E Tyson, Avroy A Fanaroff, Betty R Vohr, Rebecca Perritt, Barbara J Stoll, Richard A Ehrenkranz, Waldemar A Carlo, Seetha Shankaran, Kenneth Poole, Linda L Wright.   

Abstract

OBJECTIVE: To assess the association between peak total serum bilirubin (PSB) levels during the first 2 weeks of life and neurodevelopmental outcomes of extremely low birth weight (ELBW) infants at 18 to 22 months' postmenstrual age.
METHODS: A retrospective analysis was conducted of a cohort of ELBW infants (401-1000 g) who survived to 14 days of age in the 12 participating centers of the National Institute of Child Health and Human Development Neonatal Research Network between January 1, 1994, and December 31, 1997. Demographic and clinical risk factors and PSB levels during the first 14 days were analyzed with reference to death or adverse neurodevelopmental outcomes at 18 to 22 months' postmenstrual age. The neurodevelopmental variables considered were Psychomotor Developmental Index (PDI) <70, Mental Developmental Index (MDI) <70, moderate or severe cerebral palsy (CP), hearing impairment (needs hearing aids), and a composite category designated as neurodevelopmental impairment (NDI). The NDI is defined as infants with any 1 or more of the following: PDI <70, MDI <70, moderate to severe CP, bilateral blindness, or bilateral hearing impairment requiring amplification.
RESULTS: The subjects of this cohort analysis are infants who were admitted to the Network centers during calendar years 1994-1997 and survived beyond 14 days and had PSB recorded during the 14-day period. From this cohort, 3246 infants survived at discharge, 79 died after discharge, and 592 were lost to follow-up. Thus, 2575 of 3167 infants were seen in the follow-up clinics with a compliance rate of 81%. Logistic regression analysis showed that various demographic and clinical variables are associated with poor neurodevelopmental outcomes. After adjustment for these risk factor, significant association were found between PSB (mg/dL) and death or NDI (odds ratio: 1.068; 95% confidence interval [CI]: 1.03-1.11); PDI <70 (R = 1.057; 95% CI: 1.00-1.12), and hearing impairment requiring hearing aids (odds ratio: 1138; 95% CI: 1.00-1.30). There was no significant association between PSB (mg/dL) and CP, MDI <70, and NDI.
CONCLUSIONS: PSB concentrations during the first 2 weeks of life are directly correlated with death or NDI, hearing impairment, and PDI <70 in ELBW infants. The statistical association based on retrospective analysis of observational data and relatively small effect size should be interpreted with caution. Furthermore, because of the possibility of compounding effects of variables on outcome, the potential benefits of moderate hyperbilirubinemia and the potential adverse effects of phototherapy, a randomized, controlled trial of aggressive and conservative phototherapy is needed to address this controversial issue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523165     DOI: 10.1542/peds.112.4.773

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  26 in total

1.  A randomized trial of aggressive versus conservative phototherapy for hyperbilirubinemia in infants weighing less than 1500 g: Short- and long-term outcomes.

Authors:  Krista A Jangaard; Michael J Vincer; Alexander C Allen
Journal:  Paediatr Child Health       Date:  2007-12       Impact factor: 2.253

2.  William A Silverman lecture.

Authors:  D K Stevenson
Journal:  J Perinatol       Date:  2013-08-22       Impact factor: 2.521

3.  Association between peak serum bilirubin and neurodevelopmental outcomes in term babies with hyperbilirubinemia.

Authors:  Thirunavukkarasu Arun Babu; Vishnu Bhat B; Noyal Mariya Joseph
Journal:  Indian J Pediatr       Date:  2011-06-25       Impact factor: 1.967

Review 4.  Impact of bilirubin-induced neurologic dysfunction on neurodevelopmental outcomes.

Authors:  Courtney J Wusthoff; Irene M Loe
Journal:  Semin Fetal Neonatal Med       Date:  2015-01-10       Impact factor: 3.926

Review 5.  Bilirubin Binding Capacity in the Preterm Neonate.

Authors:  Sanjiv B Amin
Journal:  Clin Perinatol       Date:  2016-02-28       Impact factor: 3.430

6.  Unbound bilirubin measurements by a novel probe in preterm infants.

Authors:  Thomas Hegyi; Alan Kleinfeld; Andrew Huber; Barry Weinberger; Naureen Memon; Weichung Shih; Mary Carayannopoulos; William Oh
Journal:  J Matern Fetal Neonatal Med       Date:  2018-03-12

Review 7.  Auditory neuropathy--neural and synaptic mechanisms.

Authors:  Tobias Moser; Arnold Starr
Journal:  Nat Rev Neurol       Date:  2016-02-19       Impact factor: 42.937

8.  Hyperbilirubinemia diminishes respiratory drive in a rat pup model.

Authors:  Oded Mesner; Martha J Miller; Sabine C Iben; K C Prabha; Catherine A Mayer; Musa A Haxhiu; Richard J Martin
Journal:  Pediatr Res       Date:  2008-09       Impact factor: 3.756

9.  Aggressive vs. conservative phototherapy for infants with extremely low birth weight.

Authors:  Brenda H Morris; William Oh; Jon E Tyson; David K Stevenson; Dale L Phelps; T Michael O'Shea; Georgia E McDavid; Rebecca L Perritt; Krisa P Van Meurs; Betty R Vohr; Cathy Grisby; Qing Yao; Claudia Pedroza; Abhik Das; W Kenneth Poole; Waldemar A Carlo; Shahnaz Duara; Abbot R Laptook; Walid A Salhab; Seetha Shankaran; Brenda B Poindexter; Avroy A Fanaroff; Michele C Walsh; Maynard R Rasmussen; Barbara J Stoll; C Michael Cotten; Edward F Donovan; Richard A Ehrenkranz; Ronnie Guillet; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

10.  Hyperbilirubinemia and language delay in premature infants.

Authors:  Sanjiv B Amin; Diane Prinzing; Gary Myers
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.